Robert Ghenchev
Directeur/Membre du Conseil chez OXFORD BIOMEDICA PLC
Profil
Robert Ghenchev is currently a Non-Executive Director at Oxford Biomedica Plc, a Director at Mission Bio, Inc., a Director at Exscientia AI Ltd., a Director at Exscientia Plc, a Director at Mightyowl, Inc., a Director at Quanta Dialysis Technologies, Inc., a Partner & Head of Novo Growth at Novo Principal Investments, a Senior Partner & Head of Novo Growth at Novo Holdings A, and a Managing Partner at Novo Holdings Equity Us, Inc. He previously worked as a Director at Tempus AI, Inc. and as a Senior Vice President at Moelis & Co. (UK) LLP.
He graduated from the University of Oxford and holds an undergraduate degree from McGill University.
Postes actifs de Robert Ghenchev
| Sociétés | Poste | Début |
|---|---|---|
| OXFORD BIOMEDICA PLC | Directeur/Membre du Conseil | 24/06/2019 |
| EXSCIENTIA PLC | Directeur/Membre du Conseil | 01/05/2020 |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Directeur/Membre du Conseil | 01/01/2018 |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01/01/2018 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | 01/05/2020 |
Mission Bio, Inc.
 Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
| Mightyowl, Inc. | Directeur/Membre du Conseil | - |
| Novo Holdings Equity Us, Inc. | Corporate Officer/Principal | - |
| Quanta Dialysis Technologies, Inc. | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert Ghenchev
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░ ░░░ ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Robert Ghenchev
| University of Oxford | Graduate Degree |
| McGill University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| OXFORD BIOMEDICA PLC | Health Technology |
 | Technology Services |
| EXSCIENTIA PLC | Health Technology |
| Entreprise privées | 8 |
|---|---|
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Moelis & Co. (UK) LLP
 Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Finance |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Commercial Services |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
| Mightyowl, Inc. | |
| Novo Holdings Equity Us, Inc. | |
| Quanta Dialysis Technologies, Inc. |
